- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01687595
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
A Phase 2a, Multicenter, Double-blinded, Randomized, 2-Period Trial to Evaluate the Effect of HerpV Administered in Combination With the Stimulon® Adjuvant QS-21 on Viral Shedding in Adults With Recurrent Genital Herpes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the biological effectiveness and safety of the HerpV vaccine in combination with adjuvant QS-21. The Safety and tolerability of HerpV plus QS-21 will also be evaluated by collecting number and severity of adverse events throughout the study.
Participants will undergo a baseline/ screening period. This is a 45 day period when the participant collects a swab of the genital area each day. In case of a recurrence, participant will be required to collect two swabs a day. If the participant collects at least 80% of the swabbing samples and meets all eligibility criteria they may enroll in the study.
Study Period 1 consists of three treatments and a 45 day swabbing period after the last treatment. The participant will collect swabs of the genital region each day for 45 days.
Participants who successfully complete Study Period 1 will proceed to Study Period 2. They will receive a booster injection of study drug or placebo according to their original randomization assignment. The participants will again enter a 45 day swabbing period, collecting swabs of the genital area each day for 45 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Westover Heights Clinic
-
-
Texas
-
Houston, Texas, United States, 77030
- Center for Clinical Studies - Texas Medical Center
-
Houston, Texas, United States, 77065
- Center for Clinical Studies - Cypress
-
Houston, Texas, United States, 77598
- Center for Clinical Studies- Webster
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington Virology Research Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Seropositive for herpes simplex virus type 2 (HSV-2)
- Clinically active genital herpes defined as a history of 1-9 episodes per year for at least 1 year prior to screening or 1 year prior to beginning suppressive therapy.
- Willing to either use an effective method of contraception or abstain from sexual intercourse throughout the 48-week study period.
- If female of childbearing potential, have a negative serum pregnancy test.
- Agree to not receive any other investigational drugs while enrolled in this study.
- The above criteria must be met before participants are allowed to enter the 45-day swabbing period to be screen for the study.
- Completion and collection of greater than or equal to 80% (36 days) of the 45-day consecutive daily genital swabs.
Exclusion Criteria:
- Severe active infection, compromised cardiopulmonary function, or other serious medical illness that, in the opinion of the principal investigator, would prevent study completion.
- A history of herpes simplex virus (HSV) infection of the eye (herpes simplex interstitial keratitis or uveitis), or herpes-associated erythema multiforme.
- A history of immune suppression or autoimmune disorder.
- Continued use of suppressive anti-viral therapy for HSV-2; a 1 week washout of any anti-viral therapy (suppressive and episodic) is required prior to initiating the swabbing period.
- Concomitant use of systemic corticosteroids or immune-suppressive medications. The use of nasal steroids is acceptable.
- Human immunodeficiency virus (HIV) positive.
- Presence of active Hepatitis B or C infection.
- Known hypersensitivity or allergies to acyclovir or valacyclovir.
- Pregnant or breast-feeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HerpV 240 μg + QS-21 50 μg
Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1.
At Week 24, participants who completed treatment period 1 will receive a booster dose of combination of HerpV 240 μg and QS-21 50 μg in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
|
HerpV (recombinant human heat shock protein 70 [rh-Hsc70] polyvalent peptide complex) in combination with adjuvant QS-21
Other Names:
|
Placebo Comparator: Placebo
Participants will receive a placebo injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1 and at Week 24 in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
|
phosphate buffered saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13)
Time Frame: Baseline, Weeks 6-13
|
The viral shedding rate was defined as the number of days with genital swab positive for herpes simplex virus (HSV) deoxyribonucleic acid (DNA), as measured by quantitative real-time polymerase chain reaction (PCR), relative to the total number of days with available swabs. The viral shedding rate was defined as the number of days with genital swab positive for herpes simplex virus (HSV) deoxyribonucleic acid (DNA), as measured by quantitative real-time polymerase chain reaction (PCR), relative to the total number of days with available swabs. Overall viral shedding rate = number of days with positive PCR/total number of days PCR results collected. Change in overall viral shedding rate was calculated within participants comparing baseline with post-treatment, and summarized across all participants. Percent change in viral shedding rate and 95% CI are reported. |
Baseline, Weeks 6-13
|
Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 26 to 33)
Time Frame: Baseline, Weeks 26-33
|
The viral shedding rate was defined as the number of days with genital swab positive for HSV DNA, as measured by quantitative real-time PCR, relative to the total number of days with available swabs. The viral shedding rate was defined as the number of days with genital swab positive for herpes simplex virus (HSV) deoxyribonucleic acid (DNA), as measured by quantitative real-time polymerase chain reaction (PCR), relative to the total number of days with available swabs. Overall viral shedding rate = number of days with positive PCR/total number of days PCR results collected. Change in overall viral shedding rate was calculated within participants comparing baseline with post-treatment, and summarized across all participants. Percent change in viral shedding rate and 95% CI are reported. |
Baseline, Weeks 26-33
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Peripheral Blood Mononuclear Cell Immune Response at Any Time
Time Frame: Baseline through Week 26
|
Baseline through Week 26
|
Number of Participants With CD8+ Immune Response at Any Time
Time Frame: Baseline through Week 26
|
Baseline through Week 26
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Agenus Medical Monitor, Agenus Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-400-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes Simplex Type 2
-
Genocea Biosciences, Inc.CompletedGenital Herpes Simplex Type 2United States
-
Genocea Biosciences, Inc.CompletedGenital Herpes Simplex Type 2United States
-
Genocea Biosciences, Inc.CompletedGenital Herpes Simplex Type 2United States
-
Global Research InstituteRational Vaccines IncRecruitingHIV Disease | Herpes Simplex 2 | Herpes Simplex 1United States
-
VicalCompletedGenital Herpes Simplex Type 2United States
-
Fred Hutchinson Cancer CenterUniversity of Washington; Sanofi Pasteur, a Sanofi CompanyCompleted
-
Focus Diagnostics, Inc.CompletedHerpes Simplex Virus 2United States
-
New York State Psychiatric InstituteAlzheimer's AssociationActive, not recruitingMild Cognitive Impairment | Herpes Simplex 2 | Herpes Simplex 1United States
-
Nearmedic Plus LLCCompletedHerpes Simplex | Herpes Genitalis | Herpes | Herpes Oral | Herpes Simplex 2Russian Federation
-
Genocea Biosciences, Inc.Completed
Clinical Trials on HerpV and QS-21
-
University of Kansas Medical CenterTargovax ASANot yet recruiting
-
National Cancer Institute (NCI)CompletedFollicular Lymphoma | B Cell Lymphoma | NeoplasmUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroblastoma | High-risk Neuroblastoma | Metastatic NeuroblastomaUnited States
-
PfizerJANSSEN Alzheimer Immunotherapy Research & Development, LLCCompletedAlzheimer DiseaseUnited States
-
PfizerJanssen Alzheimer Immunotherapy (JAI) Research and Development, LLCCompletedAlzheimer DiseaseSpain, France, Germany
-
Agenus Inc.Completed
-
PfizerJANSSEN Alzheimer Immunotherapy Research & Development, LLCTerminatedAlzheimer DiseaseUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroblastomaUnited States
-
PfizerJANSSEN Alzheimer Immunotherapy Research & Development, LLCCompletedAlzheimer's DiseaseUnited States
-
National Institute of Allergy and Infectious Diseases...Completed